<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - 2011 discharge: Initiative on Innovative Medicines Joint Undertaking (A7-0088/2013 - Gerben-Jan Gerbrandy) - Wednesday, 17 April 2013</title><meta name="title" content="Verbatim report of proceedings - 2011 discharge: Initiative on Innovative Medicines Joint Undertaking (A7-0088/2013 - Gerben-Jan Gerbrandy) - Wednesday, 17 April 2013" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2013 - Source: European Parliament" /><meta name="available" content="17-04-2013" /><meta name="sipade-leg" content="7" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - 2011 discharge: Initiative on Innovative Medicines Joint Undertaking (A7-0088/2013 - Gerben-Jan Gerbrandy) - Wednesday, 17 April 2013" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-7-2013-04-17-ITM-007-53_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li class="hr" title="hr - hrvatski">hr - hrvatski</li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-7-2013-04-17-ITM-007-53_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-04-17-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-04-17-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-04-17-ITM-007-52_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-04-17-ITM-007-52_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-7-2013-04-17-ITM-007-54_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-7-2013-04-17-ITM-007-54_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-04-17_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-04-17_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2012/2219(DEC)">2012/2219(DEC)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A7-0088/2013</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-7-2013-0088_EN.html" class="ring_ref_link">A7-0088/2013</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p>
                        <a href="/doceo/document/PV-7-2013-04-16-ITM-013_EN.html" class="ring_ref_link">PV 16/04/2013 - 13</a><br />
                        <a href="/doceo/document/CRE-7-2013-04-16-ITM-013_EN.html" class="ring_ref_link">CRE 16/04/2013 - 13</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-7-2013-04-17-ITM-012-44_EN.html" class="ring_ref_link">PV 17/04/2013 - 12.44</a><br />
                        <a class="ring_ref_selected">Explanations of votes</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-7-2013-0169_EN.html" class="ring_ref_link">P7_TA(2013)0169</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Wednesday, 17 April 2013 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 7.53. 2011 discharge: Initiative on Innovative Medicines Joint Undertaking (<a href="/doceo/document/A-7-2013-0088_EN.html">A7-0088/2013</a> - Gerben-Jan Gerbrandy) </td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20130417-14:37:54&amp;playerEndTime=20130417-14:39:10" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20130417-14:37:54&amp;playerEndTime=20130417-14:39:10" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20130417-14:37:54&amp;playerEndTime=20130417-14:39:10" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td></tr></table>
<a name="3-685-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Dichiarazioni di voto orali</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-686-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96824.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130417-14:38:14&amp;playerEndTime=20130417-14:38:59" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Monica Luisa Macovei (PPE). - </span></span>  Mr President, the Initiative on Innovative Medicines Joint Undertaking has received positive remarks from the Court of Auditors on the reliability of its accounts and financial transactions. The undertaking was designed to significantly improve the drug development process, with a view to producing more effective and safer innovative medicines. The 66% implementation rate for research activities relates to the call for proposals remaining at the same level. The total available Union contribution will not be used. Therefore, the Joint Undertaking has to make the best possible use of the allocated resources and to make the changed needed.</p>
<p class="contents">I note the Court of Auditors’ positive reports regarding the internal control system in 2011, but further reforms are needed in relation to the budget and accounting procedures and the mechanism of control.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-687-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Dichiarazioni di voto scritte</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-687-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96976.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Luís Paulo Alves (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Aprovo o presente relatório, começando por manifestar a minha preocupação relativamente ao facto de a taxa de execução das dotações de autorização disponíveis para atividades de investigação ter sido de 66 %, tendo sido executada através de uma autorização global para o quarto convite à apresentação de propostas. Reitero a preocupação quanto à baixa taxa de execução do orçamento e quanto às atividades subjacentes da Empresa Comum, observando que o número elevado de dotações não utilizadas do orçamento administrativo (44 %) indica que o mesmo não se baseou em estimativas realistas. Deste modo, solicito a apresentação ao Parlamento Europeu de um relatório pormenorizado sobre a evolução das deficiências mencionadas, que inclua propostas concretas para uma melhoria gradual da taxa de execução e para uma estimativa mais realista dos recursos financeiros necessários.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-687-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96862.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sophie Auconie (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> L'entreprise commune IMI met en œuvre l'initiative technologique conjointe (ITC) en matière de médicaments innovants dans la perspective du développement d'un secteur pharmaceutique compétitif basé sur l'innovation. Ce partenariat public-privé vise à soutenir les investissements dans ce domaine. J'ai voté en faveur de la décharge sur l'exécution du budget de l'entreprise commune pour la mise en œuvre de l'initiative technologique conjointe en matière de médicaments innovants pour l'exercice 2011.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-687-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96680.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zigmantas Balčytis (S&amp;D), </span></span>  <span class="italic">raštu</span><span class="bold">. −</span> Atsižvelgiant į palankią Audito Rūmų ataskaitą dėl Bendrosios įmonės 2011 finansinių metų metinių finansinių ataskaitų, nėra kliūčių nepritarti Bendrosios įmonės 2011 m. biudžeto įvykdymo patvirtinimui. Tačiau Audito Rūmai pateikė sąlyginę nuomonę dėl Bendrosios įmonės finansinėse ataskaitose atspindimų operacijų teisėtumo ir tvarkingumo. Bendroji įmonė „Naujoviški vaistai“ buvo įsteigta 2007 m. gruodžio mėn. dešimties metų laikotarpiui siekiant gerokai pagerinti vaistų kūrimo proceso našumą bei veiksmingumą ir siekiant ilgalaikio tikslo, kad farmacijos sektorius gamintų veiksmingesnius ir saugesnius naujoviškus vaistus. Auditų metu nustatytas klaidų lygis sudarė 6,84 proc., todėl Bendroji įmonė turėtų nedelsdama padidinti savo <span class="italic">ex ante</span> kontrolės kokybę, ypač dotacijų valdymo srityje, informuoti biudžeto įvykdymą tvirtinančią instituciją apie tolesnių Bendrosios įmonės vykdytų <span class="italic">ex post</span> audito procesų rezultatus bei parengti išsamią pažangos ataskaitą su konkrečiais pasiūlymais, kaip palaipsniui sumažinti klaidų lygį.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-687-937"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96814.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elena Băsescu (PPE), </span></span>  <span class="italic">în scris</span><span class="bold">. −</span> Am votat în favoarea raportului, deoarece Curtea de Conturi a exprimat o opinie cu rezerve privind legalitatea şi regularitatea operaţiunilor subiacente conturilor Întreprinderii comune pentru punerea în aplicare a iniţiativei tehnologice comune privind medicamentele inovatoare. Constat cu îngrijorare că bugetul Întreprinderii comune pentru exerciţiul financiar 2011 şi planul de aplicare au fost adoptate de Consiliul de conducere abia la 4 aprilie 2011, din cauza timpului necesar stabilirii de comun acord a priorităţilor ştiinţifice care urmau să fie incorporate în planul anual de aplicare. De asemenea, este îngrijorător faptul că, deşi Întreprinderea comună şi-a obţinut autonomia în noiembrie 2009, nu s-au efectuat activităţi de audit intern de asigurare ca atare până în martie 2012, nici de către Serviciul de Audit Intern al Comisiei, nici de către directorul de audit intern şi acesta din urmă a participat în mod direct la o serie de activităţi operaţionale, precum şi la alte misiuni de consultanţă.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-688-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97198.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mara Bizzotto (EFD), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>Pur condividendo l'analisi contenuta nella relazione del collega Gerbrandy, non ho ritenuto concedere il discarico all'IMI, per il periodo di esercizio 2011</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-688-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/105624.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Philippe Boulland (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai approuvé la décharge 2011 de l'entreprise commune pour la mise en œuvre de l'initiative technologique conjointe en matière de médicaments innovants. Par le biais de la décharge, le Parlement contrôle politiquement l'exécution du budget, et peut sanctionner une institution ou agence qui aurait failli à ses obligations. Ici, j'ai estimé que l'utilisation des fonds pour l'exercice 2011 avait été tout à fait régulière.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-688-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96798.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">John Bufton (EFD), </span></span>  <span class="italic">in writing</span><span class="bold">. −</span> I voted against the Initiative on Innovative Medicines Joint Undertaking as it demonstrates a lack of transparency and was not created with the consent of my voters or constituents. In this time of austerity, the existence of this agency is neither useful nor necessary.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-688-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96826.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tamás Deutsch (PPE), </span></span>  <span class="italic">írásban</span><span class="bold">. −</span> Az Európai Számvevőszék 2011-es pénzügyi évre vonatkozó éves jelentésének bemutatását követően a 2011. évi zárszámadási eljárás keretében az Európai Parlament Költségvetési Ellenőrző Bizottsága elvégezte az Európai Unió általános költségvetésének az innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító közös vállalkozásra vonatkozó pénzügyi ellenőrzését. A szakbizottság elsődleges feladata a közösségi költségvetés végrehajtásának szabályosságát és hatékonyságát ellenőrizni. A jelentés aggodalommal állapítja meg, hogy a közös vállalkozás igazgatótanácsa a 2011-es évre vonatkozóan csak 2011. április 4-én fogadta el a költségvetést és annak végrehajtási tervét. A jelentés továbbá kiemeli, hogy a közös vállalkozás ügyvezető igazgatója 2012 februárjában úgy adott ki egy megbízhatósági nyilatkozatot, hogy az ex-post ellenőrzési stratégiára vonatkozó hatékonysági információk birtokában sem voltak. A zárszámadási jelentés felhívja a figyelmet arra, hogy a pénzügyi átvilágítás rendben lezajlott és nagyobb hiányosságokat nem állapított meg az innovatív gyógyszerek kutatására irányuló kezdeményezés területén. A szakbizottság márciusi ülésén a mentesítés megadásáról, a 2011-es számlák lezárásáról döntött. A szakbizottsági szavazáson és a plenáris szavazáson is a mentesítés megadását támogattam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-688-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28310.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Edite Estrela (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Votei favoravelmente o relatório relativo à Quitação orçamental de 2011 da Empresa Comum para a execução da iniciativa tecnológica conjunta sobre medicamentos inovadores, por considerar que esta parceria público-privada desempenha um papel muito importante para a concretização das políticas europeias, nomeadamente na investigação e desenvolvimento de medicamentos mais eficazes e seguros, com claros benefícios para os cidadãos.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-688-937"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4550.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jill Evans (Verts/ALE), </span></span>  <span class="italic">in writing</span><span class="bold">. −</span> I voted in favour of this discharge because I am satisfied with the budget performance and monitoring. It is important to my constituents in Wales that public money is spent effectively.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-688-968"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96977.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Diogo Feio (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> No atual momento político, quando muitos dos Estados da União Europeia, em especial o meu, atravessam dificuldades sem paralelo na história recente, mais do que centrar-me no relatório que aqui estou a votar sobre as contas da Empresa Comum para a execução da iniciativa tecnológica conjunta sobre medicamentos inovadores, gostaria de deixar algumas considerações mais gerais. Desde logo, gostaria de apelar a que todas estas instituições, serviços e agências da UE adotassem um princípio de boa gestão e uma política de contenção e austeridade relativamente aos seus gastos. O Orçamento da UE, para além dos recursos próprios, vem, essencialmente, das contribuições dos Estados, razão pela qual se exige, na atual conjuntura, uma especial contenção de despesas e a adequação das regras internas a uma política ativa que combata o desperdício e que institua normas claríssimas de boa gestão e de eficácia na utilização de dinheiros públicos. Não é possível que a UE continue a exigir difíceis ajustamentos aos Estados, quando nas suas instituições, serviços e agências ainda há inúmeros casos de má gestão e de falta de transparência.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-689-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23868.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Monika Flašíková Beňová (S&amp;D), </span></span>  <span class="italic">písomne</span><span class="bold">. −</span> Spoločný podnik pre vykonávanie spoločnej technologickej iniciatívy pre inovačné lieky bol zriadený v decembri 2007 na obdobie 10 rokov s cieľom významne zvýšiť efektívnosť a účinnosť procesu vývoja liekov s dlhodobým zámerom, aby farmaceutické odvetvie vyrábalo účinnejšie a bezpečnejšie inovačné lieky. Samostatne začal fungovať v novembri 2009. Podľa prehlásení Dvoru audítorov, účtovná závierka spoločného podniku za rozpočtový rok 2011 je spoľahlivá a príslušné operácie sú zákonné a správne. Európsky parlament teda ročnú účtovnú závierku schvaľuje a zároveň, rozhodol sa udeliť výkonnému riaditeľovi spoločného podniku pre vykonávanie spoločnej technologickej iniciatívy pre inovačné lieky absolutórium za plnenie rozpočtu spoločného podniku za rozpočtový rok 2011.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-689-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96693.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Juozas Imbrasas (EFD), </span></span>  <span class="italic">raštu</span><span class="bold">. −</span> Pritariau tam, kad būtų patvirtinta bendrosios įmonės siekiant įgyvendinti jungtinę technologijų iniciatyvą „Naujoviški vaistai“ 2011 finansinių metų sąskaitų uždarymui. Bendroji įmonė įsteigta siekiant įgyvendinti jungtinę technologijų iniciatyvą „Naujoviški vaistai“ dešimties metų laikotarpiui. Įsteigta siekiant gerokai pagerinti vaistų kūrimo proceso našumą bei veiksmingumą ir siekiant ilgalaikio tikslo, kad farmacijos sektorius gamintų veiksmingesnius ir saugesnius naujoviškus vaistus. Audito Rūmai pranešė, jog jiems pateiktas pagrįstas patikinimas, kad Bendrosios įmonės 2011 finansinių metų metinės ataskaitos yra patikimos ir jose nurodytos operacijos yra teisėtos ir tvarkingos.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-689-281"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/101580.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Constance Le Grip (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> La décharge est la dernière étape de la procédure budgétaire européenne. Après audit et validation finale des comptes, le Conseil émet une recommandation avant que le Parlement accepte de donner ou non la décharge du budget, qui vient libérer la Commission de son obligation de gestion. Le résultat de l'examen des comptes ayant été satisfaisant et avec la recommandation positive du Conseil, j'ai voté pour donner décharge du budget de l'entreprise commune pour la mise en œuvre de l'initiative technologique conjointe en matière de médicaments innovants.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-689-312"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1403.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">David Martin (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. −</span> I voted for this report which, ‘Is concerned that the annual accounts of the Joint Undertaking received a qualified opinion from the Court of Auditors on the legality and the regularity of the transactions underlying those accounts on the grounds that the error rate resulting from the ex-post audits was 6.84 %; takes note that the Joint Undertaking completed ex-post audits covering EUR 2.2 million (18.8 % of the accepted Joint Undertaking's contribution for the first call validated by the Joint Undertaking by June 2011); regrets that based on Joint Undertaking first audits applying its own methodology the detected error rate was 4.58 % while the residual error rate was 3.72 %; expects that the Court and the Joint Undertaking agree on an audit methodology that for the same ex-post audits delivers the same results, reiterates that the Joint Undertaking should reinforce without delay the quality of its ex-ante controls in particular for the grant management, requests that the discharge authority is informed of the results of the following ex-post audit processes conducted by the Joint Undertaking’.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-689-375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96978.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nuno Melo (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Todas as instituições europeias que dependem do orçamento da União Europeia têm que ser fiscalizadas, de forma rigorosa, pelo Tribunal de Contas e por todas as entidades com essa função. É necessário aferir se os fundos comunitários estão a ser bem utilizados, se essas instituições estão a cumprir com os objetivos delineados e se não existe desperdício de recursos. De um modo geral, salvo raras exceções, a avaliar pelas fiscalizações conhecidas, podemos afirmar que as instituições em causa estão a utilizar de forma correta os fundos disponibilizados e a cumprir com os objetivos propostos. É nesse sentido o voto favorável relativamente ao relatório de quitação da Empresa Comum para a execução da iniciativa tecnológica conjunta sobre medicamentos inovadores.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-689-437"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28407.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Willy Meyer (GUE/NGL), </span></span>  <span class="italic">por escrito</span><span class="bold">. −</span> He votado a favor del presente informe por suponer una buena fuente de información sobre la gestión y el papel que ha desempeñado en 2011 la Empresa Común para la Iniciativa sobre Medicamentos Innovadores. Este informe sostiene que la gestión de esta Empresa Común se ha desarrollado de forma regular y acorde a la normativa existente. Elaborar buenos informes que investiguen la gestión de las instituciones es una herramienta fundamental para un control efectivo de las mismas. El ponente mantiene un control exhaustivo sobre todas las partidas de dicha Empresa Común, lo que mejora la transparencia y el control de las agencias públicas europeas. Considero que este informe es un avance al exponer de una manera crítica y veraz el rol de la Empresa Común para la Iniciativa sobre Medicamentos Innovadores. Por todo lo que esto representa para una gestión responsable de los fondos públicos, he votado a favor de este informe.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-689-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96760.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tiziano Motti (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>Il consiglio di direzione dell’Agenzia per i medicinali ha adottato il bilancio dell'impresa comune per l'esercizio 2011 e il piano di attuazione solamente il 4 aprile 2011 a causa del tempo richiesto per fissare e concordare le priorità scientifiche da includere nel piano di attuazione annuale. Questo ha ritardato la pubblicazione dell'invito a presentare proposte e per l'intero primo trimestre dell'anno l'impresa comune è stata quindi costretta a ricorrere al regime di bilancio dei dodicesimi provvisori per effettuare i pagamenti. Il tasso di esecuzione dei 159 000 000 EUR di stanziamenti d'impegno disponibili per le attività di ricerca è stato del 66% e l'esecuzione è avvenuta attraverso un impegno globale relativo al quarto invito a presentare proposte; non possiamo che ribadire la nostra preoccupazione per il basso tasso di esecuzione del bilancio e chiediamo una relazione dettagliata sui progressi compiuti in merito a tali carenze. </p>
<p class="contents">.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-689-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96902.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Maria do Céu Patrão Neves (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Votei favoravelmente a proposta de quitação pela execução do orçamento da Empresa Comum para a execução da iniciativa tecnológica conjunta sobre medicamentos inovadores para o exercício de 2011 tendo por base o relatório anual do Tribunal de Contas sobre a execução do orçamento para o exercício de 2011, acompanhado da resposta do Instituto, a declaração relativa à fiabilidade das contas e à legalidade e regularidade das operações subjacentes, emitida pelo Tribunal de Contas para o exercício de 2011 nos termos do artigo 287.º do TFUE, bem como do parecer favorável da Comissão do Controlo Orçamental do Parlamento Europeu. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-689-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96903.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Paulo Rangel (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> Ao dar quitação a uma instituição ou agência, o Parlamento Europeu aprova a boa utilização do erário público na execução orçamental, alcançada no respeito pela regulamentação. Após recomendação do Conselho, os deputados ao Parlamento Europeu são chamados a exercer controlo sobre a gestão das dotações, decidindo sobre a quitação com base nos relatórios do Tribunal de Contas. No que concerne ao orçamento da Empresa Comum para a execução da iniciativa tecnológica conjunta sobre medicamentos inovadores para o exercício de 2011, e avaliados os relatórios do Tribunal de Contas e da Comissão Parlamentar do Controlo Orçamental, apoiei a quitação à execução do orçamento. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-690-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23821.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">József Szájer (PPE), </span></span>  <span class="italic">írásban</span><span class="bold">. −</span> A 2011. évi zárszámadási eljárás keretében a Számvevőszék éves jelentése, valamint a Költségvetési Ellenőrző Bizottság ajánlása alapján szavazatommal támogatom, hogy a Parlament mentesítést adjon az Innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító közös vállalkozás ügyvezető igazgatója számára a közös vállalkozás 2011-es pénzügyi évre szóló költségvetésének végrehajtására vonatkozóan.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-691-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29579.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marc Tarabella (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur de cette décharge. Cependant, le budget de l'entreprise commune pour l'exercice 2011 et le plan d'exécution n'ont été adoptés par le comité directeur que le 4 avril 2011 en raison du temps qu'il a fallu pour établir et approuver les priorités scientifiques à inclure dans le plan d'exécution annuel. Cela a retardé le lancement de l'appel de propositions et, pendant tout le premier trimestre, l'entreprise commune a dû utiliser le régime des douzièmes provisoires pour effectuer les paiements. </p>
<p class="contents">Je m'inquiète de ce que la Cour des comptes ait émis une opinion avec réserves sur la légalité et la régularité des opérations sous-jacentes aux comptes annuels de l'entreprise commune au motif que le taux d'erreur relevé dans le cadre des audits ex post était de 6,84 %. L'entreprise commune a terminé des audits ex post couvrant un montant de 2 200 000 EUR (soit 18,8 % de la contribution que l'entreprise commune a accepté de verser pour le premier appel qu'elle a validé en juin 2011). </p>
<p class="contents">Je déplore également que, sur la base de l'application de la méthodologie de l'entreprise commune, les taux d'erreur détecté et résiduel s'élèvent respectivement à 4,58 % et 3,72 %</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-691-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96974.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nuno Teixeira (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">−</span> O Parlamento Europeu deve dar quitação a uma instituição ou agência, declarando assim que a mesma respeitou a regulamentação europeia na execução orçamental e dá por terminado o respetivo orçamento. O Parlamento Europeu pode recusar ou adiar a quitação orçamental. Voto favoravelmente a quitação da Empresa Comum para a execução da iniciativa tecnológica conjunta sobre medicamentos inovadores, salientando que esta visa melhorar significativamente a eficácia e a eficiência do processo de desenvolvimento de fármacos de modo a que o setor farmacêutico produza, a longo prazo, medicamentos inovadores mais eficazes e mais seguros.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-691-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/36281.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Silvia-Adriana Ţicău (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. − </span>Am votat pentru decizia Parlamentului European privind descărcarea de gestiune pentru execuția bugetului Întreprinderii comune pentru punerea în aplicare a inițiativei tehnologice comune privind medicamentele inovatoare aferent exercițiului financiar 2011. Întreprinderea comună pentru punerea în aplicare a inițiativei tehnologice comune privind medicamentele inovatoare (denumită în continuare „Întreprinderea comună”) a fost înființată în decembrie 2007 pentru o perioadă de 10 ani pentru a îmbunătăți în mod semnificativ eficiența și eficacitatea procesului de dezvoltare a produselor medicamentoase, pentru ca, pe termen lung, sectorul farmaceutic să producă medicamente inovatoare mai eficace și mai sigure. Parlamentul European este îngrijorat că rata de execuție a creditelor de angajament, în valoare de 159 000 000 EUR, care erau disponibile pentru activități de cercetare, a fost de 66% și că aceste credite au fost executate sub forma unui angajament global care acoperă cea de-a patra cerere de propuneri. Se constată că volumul ridicat de credite neutilizate din cadrul bugetului administrativ (44%) indică faptul că acesta nu a avut la bază estimări realiste. Se solicită realizarea unui raport intermediar detaliat privind deficiențele menționate, adresat Parlamentului European, care să conțină propuneri concrete pentru îmbunătățirea treptată a ratelor de execuție și pentru estimarea mai realistă a resurselor financiare necesare. </p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
